*Doses are commonly-reported figures from public sources, not a recommendation. Educational only.
| Year | Title / venue | Source |
|---|---|---|
| 2026 | Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · preclinical | PMID 41490200 |
| 2025 | Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties International journal of molecular sciences · preclinical | PMID 40141333 |
| 2025 | Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity Biogerontology · preclinical | PMID 40908429 |
| 2025 | The Antioxidant Tetrapeptide Epitalon Enhances Delayed Wound Healing in an in Vitro Model of Diabetic Retinopathy Stem cell reviews and reports · preclinical | PMID 40493162 |
| 2022 | Epitalon protects against post-ovulatory aging-related damage of mouse oocytes in vitro Aging · preclinical | PMID 35413689 |
| 2007 | Antioxidant properties of geroprotective peptides of the pineal gland Archives of gerontology and geriatrics · preclinical | PMID 17317455 |
| 2006 | Effect of the synthetic pineal peptide epitalon on spontaneous carcinogenesis in female C3H/He mice In vivo (Athens, Greece) · preclinical | PMID 16634527 |
| 2002 | Peptides and Ageing Neuro endocrinology letters · preclinical | PMID 12374906 |
| 2002 | [Aging of the pineal gland] Advances in gerontology = Uspekhi gerontologii · preclinical | PMID 12096440 |
| 2002 | [Geroprotective effect of thymalin and epithalamin] Advances in gerontology = Uspekhi gerontologii · preclinical | PMID 12577695 |
| 2002 | Epithalon decelerates aging and suppresses development of breast adenocarcinomas in transgenic her-2/neu mice Bulletin of experimental biology and medicine · preclinical | PMID 12459848 |
| 2002 | Studies of the effects of Vilon and Epithalon on gene expression in mouse heart using DNA-microarray technology Bulletin of experimental biology and medicine · preclinical | PMID 12360356 |
| 2001 | Modulating effects of epithalamin and epithalon on the functional morphology of the spleen in old pinealectomized rats Bulletin of experimental biology and medicine · preclinical | PMID 11865335 |
| 2001 | Effects of pineal peptide preparation Epithalamin on free-radical processes in humans and animals Neuro endocrinology letters · preclinical | PMID 11335874 |
| 1994 | Artificial life extension. The epigenetic approach Annals of the New York Academy of Sciences · preclinical | PMID 8010616 |
Epithalon (Epitalon / Epithalamin (Ala-Glu-Asp-Gly)). Synthetic tetrapeptide based on the pineal peptide epithalamin. Reported to upregulate telomerase activity and modulate melatonin/circadian and neuroendocrine function in animal and limited human studies (largely from a single research group).
Commonly discussed uses: longevity research interest, circadian/sleep support (anecdotal). There is both human and animal/preclinical research, though the depth and quality vary by indication. Note: most uses are not approved indications.
Mechanism: Synthetic tetrapeptide based on the pineal peptide epithalamin. Reported to upregulate telomerase activity and modulate melatonin/circadian and neuroendocrine function in animal and limited human studies (largely from a single research group).
Reported considerations: limited independent safety data, anecdotal: well tolerated. There is both human and animal/preclinical research, though the depth and quality vary by indication. Not approved. Most efficacy claims derive from a limited body of research needing independent replication. This is not a safety endorsement; safety data for unapproved compounds is incomplete.
Commonly cited ranges (educational reference, not a recommendation): low 5mg/day, typical 5-10mg/day for ~10-20 day cycles, high 10mg/day cycled. Administration: subcutaneous, intramuscular, intranasal. Half-life: very short.
Australian status: Not ARTG-registered; research. Not approved. Most efficacy claims derive from a limited body of research needing independent replication. General regulatory context: most active peptides are Schedule 4 and require a prescription; import via the Personal Importation Scheme requires a valid Australian prescription for prescription-only goods.
Reconstitution/storage reference: 2-3ml BAC water per 10-50mg vial; storage: refrigerated.
Commonly discussed combinations (anecdotal for unapproved compounds): Epithalon cycled standalone (anecdotal longevity protocol). Stacking increases interaction/safety uncertainty.